Barclays analyst Douglas Tsao believes Alkermes' Q3 earnings report highlighted key advances across its pipeline. The analyst, however, feels that "lumpiness" in Vivitrol gross-to-net over recent quarters "may warrant caution" on the drug's sales trajectory. Tsao still harbors "residual caution" on whether the FDA will accept a single Phase 3 trial for approval of ALKS-5461. Investors though will take comfort in management's reiteration of 2016 guidance, Tsao writes in a post-earnings research note. He keeps an Overweight rating on Alkermes with a $66 price target.